CUPERTINO, Calif., Oct. 27 /PRNewswire-FirstCall/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) third quarter 2008 financial results press release, you are invited to listen to the conference call that will be broadcast live over the Internet on Monday, November 3, 2008 at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time).
A live audio webcast of the presentation will be available by accessing DURECT's homepage at http://www.durect.com and clicking "Investor Relations." If you are unable to participate during the live webcast, the call will be archived on DURECT's website under Audio Archive in the "Investor Relations" section.
About DURECT Corporation
DURECT is an emerging specialty pharmaceutical company developing innovative drugs for pain and other chronic diseases, with late-stage development programs including REMOXY(TM), POSIDUR(TM), ELADUR(TM), and TRANSDUR(TM)-Sufentanil. DURECT's proprietary oral, transdermal and injectable depot delivery technologies enable new indications and superior clinical/commercial attributes such as abuse deterrence, improved convenience, compliance, efficacy and safety for small molecule and biologic drugs. For more information, please visit http://www.durect.com.
NOTE: POSIDUR(TM), SABER(TM), ORADUR(R), TRANSDUR(TM), and ELADUR(TM)
are trademarks of DURECT Corporation. Other referenced trademarks belong to
their respective owners. REMOXY, POSIDUR, ELADUR and TRANSDUR-Sufentanil
are drug candidates under development a
|SOURCE DURECT Corporation|
Copyright©2008 PR Newswire.
All rights reserved